XML 63 R47.htm IDEA: XBRL DOCUMENT v3.6.0.2
Segments of Business and Geographic Areas (Tables)
12 Months Ended
Jan. 01, 2017
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information
 
 
Sales to Customers
(Dollars in Millions)
 
2016
 
2015
 
2014
Consumer —
 
 
 
 
 
 
United States
 
$
5,420

 
5,222

 
5,096

International
 
7,887

 
8,285

 
9,400

Total
 
13,307

 
13,507

 
14,496

Pharmaceutical —
 
 
 
 
 
 
United States
 
20,125

 
18,333

 
17,432

International
 
13,339

 
13,097

 
14,881

Total
 
33,464

 
31,430

 
32,313

Medical Devices —
 
 
 
 
 
 
United States
 
12,266

 
12,132

 
12,254

International
 
12,853

 
13,005

 
15,268

Total
 
25,119

 
25,137

 
27,522

Worldwide total
 
$
71,890

 
70,074

 
74,331


 
 
Income Before Tax
 
Identifiable Assets
(Dollars in Millions)
 
2016 (3)
 
2015 (4)
 
2014 (5)
 
2016
 
2015
Consumer
 
$
2,441

 
1,787

 
1,941

 
$
23,971

 
20,772

Pharmaceutical
 
12,827

 
11,734

 
11,696

 
27,477

 
26,144

Medical Devices
 
5,578

 
6,826

 
7,953

 
39,773

 
40,979

Total
 
20,846

 
20,347

 
21,590

 
91,221

 
87,895

Less: Expense not allocated to segments (1)
 
1,043

 
1,151

 
1,027

 
 
 
 
General corporate (2)
 
 
 
 
 
 
 
49,987

 
45,516

Worldwide total
 
$
19,803

 
19,196

 
20,563

 
$
141,208

 
133,411


 
 
Additions to Property,
Plant & Equipment
 
Depreciation and
Amortization
(Dollars in Millions)
 
2016
 
2015
 
2014
 
2016
 
2015
 
2014
Consumer
 
$
486

 
544

 
581

 
$
608

 
559

 
577

Pharmaceutical
 
927

 
1,063

 
977

 
886

 
929

 
1,053

Medical Devices
 
1,472

 
1,631

 
1,807

 
1,928

 
1,945

 
1,974

Segments total
 
2,885

 
3,238

 
3,365

 
3,422

 
3,433

 
3,604

General corporate
 
341

 
225

 
349

 
332

 
313

 
291

Worldwide total
 
$
3,226

 
3,463

 
3,714

 
$
3,754

 
3,746

 
3,895

Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas
 
 
Sales to Customers
 
Long-Lived Assets (6)
(Dollars in Millions)
 
2016
 
2015
 
2014
 
2016
 
2015
United States
 
$
37,811

 
35,687

 
34,782

 
$
36,934

 
36,609

Europe
 
15,770

 
15,995

 
18,947

 
21,996

 
20,167

Western Hemisphere excluding U.S. 
 
5,734

 
6,045

 
7,160

 
2,961

 
2,881

Asia-Pacific, Africa
 
12,575

 
12,347

 
13,442

 
2,512

 
2,493

Segments total
 
71,890

 
70,074

 
74,331

 
64,403

 
62,150

General corporate
 
 
 
 
 
 
 
1,190

 
1,148

Other non long-lived assets
 
 
 
 
 
 
 
75,615

 
70,113

Worldwide total
 
$
71,890

 
70,074

 
74,331

 
$
141,208

 
133,411

­
See Note 1 for a description of the segments in which the Company operates.
Export sales are not significant. In 2016, the Company had two wholesalers distributing products for all three segments that represented approximately 13.5% and 10.7% of the total consolidated revenues. In 2015 and 2014, the Company had one wholesaler distributing products for all three segments that represented approximately 12.5% and 11.0%, respectively, of the total consolidated revenues.
(1) 
Amounts not allocated to segments include interest (income) expense and general corporate (income) expense.
(2) 
General corporate includes cash, cash equivalents and marketable securities.
(3) 
Includes net litigation expense of $806 million and a restructuring related charge of $685 million in the Medical Devices segment. The Pharmaceutical segment includes a positive adjustment of $0.5 billion to previous reserve estimates, an in-process research and development expense of $29 million, and gains from the divestitures of the controlled substance raw material and active pharmaceutical ingredient (API) business and certain anesthetic products in Europe.
(4) 
The Medical Devices segment includes a restructuring related charge of $590 million, an intangible asset write-down of $346 million related to Acclarent, Synthes integration costs of $196 million and $148 million expense for the cost associated with the DePuy ASRTM Hip program. Includes $224 million of in-process research and development expense, comprised of $214 million and $10 million in the Pharmaceutical and Medical Devices segments, respectively. Includes net litigation expense of $141 million comprised of $136 million in the Pharmaceutical segment and $5 million in the Medical Devices segment, which included the gain from the litigation settlement agreement with Guidant for $600 million. The Medical Devices Segment includes a gain of $1.3 billion from the divestiture of the Cordis business. The Pharmaceutical segment includes a gain of $981 million from the U.S. divestiture of NUCYNTA® and a positive adjustment of $0.5 billion to previous reserve estimates, including Managed Medicaid rebates. The Consumer segment includes a gain of $229 million from the divestiture of SPLENDA® brand.
(5) 
Includes net litigation expense of $1,253 million comprised of $907 million, $259 million and $87 million in the Medical Devices, Pharmaceutical and Consumer segments, respectively. Includes $178 million of in-process research and development expense, comprised of $147 million and $31 million in the Pharmaceutical and Medical Devices segments, respectively. The Medical Devices segment includes a net gain of $1,899 million from the divestiture of the Ortho-Clinical Diagnostics business, Synthes integration costs of $754 million and $126 million expense for the cost associated with the DePuy ASRTM Hip program. The Pharmaceutical segment includes an additional year of the Branded Prescription Drug Fee of $220 million and a positive adjustment of $0.1 billion to previous reserve estimates.
(6) 
Long-lived assets include property, plant and equipment, net for 2016, and 2015 of $15,912 and $15,905, respectively, and intangible assets and goodwill, net for 2016 and 2015 of $49,681 and $47,393, respectively.